6 research outputs found
International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats:The REVEAL Study
Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. Hypothesis/Objectives: Observational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH). Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death. Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean \ub1 standard deviation, 1.3 \ub1 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. Conclusions and Clinical Importance: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality
Long-term Incidence and risk of noncardiovascular and all-cause mortality in apparently healthy cats and cats with preclinical hypertrophic cardiomyopathy
Background Epidemiologic knowledge regarding noncardiovascular and allâcause mortality in apparently healthy cats (AH) and cats with preclinical hypertrophic cardiomyopathy (pHCM) is limited, hindering development of evidenceâbased healthcare guidelines. Objectives To characterize/compare incidence rates, risk, and survival associated with noncardiovascular and allâcause mortality in AH and pHCM cats. Animals A total of 1730 clientâowned cats (722 AH, 1008 pHCM) from 21 countries. Methods Retrospective, multicenter, longitudinal, cohort study. Longâterm health data were extracted by medical record review and owner/referring veterinarian interviews. Results Noncardiovascular death occurred in 534 (30.9%) of 1730 cats observed up to 15.2âyears. Proportion of noncardiovascular death did not differ significantly between cats that at study enrollment were AH or had pHCM (P =â.48). Cancer, chronic kidney disease, and conditions characterized by chronic weightâlossâvomitingâdiarrheaâanorexia were the most frequently recorded noncardiovascular causes of death. Incidence rates/risk of noncardiac death increased with age in AH and pHCM. Allâcause death proportions were greater in pHCM than AH (65% versus 40%, respectively; P <â.001) because of higher cardiovascular mortality in pHCM cats. Comparing AH with pHCM, median survival (study entry to noncardiovascular death) did not differ (AH, 9.8âyears; pHCM, 8.6âyears; P =â.10), but allâcause survival was significantly shorter in pHCM (Pâ= .0001). Conclusions and Clinical Importance Allâcause mortality was significantly greater in pHCM cats due to disease burden contributed by increased cardiovascular death superimposed upon noncardiovascular death
Structural and functional cardiovascular changes and their consequences following interventional patent ductus arteriosus occlusion in dogs: 24 cases (2000â2006)
Gamification como catalisador motivacional dos trabalhadores : uma metodologia para aumentar a produtividade
Dissertation presented as the partial requirement for obtaining a Master's degree in Information Management, specialization in Information Systems and Technologies ManagementO rĂĄpido desenvolvimento das tecnologias proporciona a alteração do modelo de negĂłcio das empresas de qualquer dimensĂŁo e permite alcançar diversos benefĂcios, principalmente econĂłmicos. Torna-se cada vez mais difĂcil aproveitar este fator para retirar maior vantagem competitiva e garantir um bom nĂvel de produtividade. As tecnologias permitem o controlo sobre a maior parte dos processos e tarefas de forma automatizada, mas os recursos humanos sĂŁo muito mais complicados de gerir e manter nĂveis de produtividade desejados devido aos inĂșmeros fatores que influenciam o desempenho individual e de grupo.
Apesar das tecnologias terem aberto este problema, estas podem tambĂ©m ser parte da solução. As TĂ©cnicas de Gamification ajudam a desenvolver soluçÔes orientadas na Ăłtica do jogo e trazem benefĂcios adicionais. Tendo em consideração a metodologia de Gamification, esta dissertação tem como o objetivo o estudo de um problema real e generalizado de falta de motivação por parte dos recursos humanos, independentemente da sua função dentro da organização, e a proposta de uma solução dentro desta metodologia que, efetivamente aumente a sua motivação e consequentemente melhore os nĂveis de produtividade